{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:26:19Z","timestamp":1792178779232,"version":"4.4.0"},"reference-count":43,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Docetaxel is the standard of care for advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy and\/or immunotherapy but is associated with modest clinical outcomes and considerable toxicity. Sacituzumab govitecan and datopotamab deruxtecan are trophoblast cell surface antigen (TROP)-2-directed antibody\u2013drug conjugates (ADCs) that showed encouraging activity in pretreated patients with advanced NSCLC. This systematic review and pooled analysis aims to comprehensively assess the efficacy and safety of anti-TROP-2 ADCs compared to docetaxel in pretreated patients with advanced NSCLC. Methods: A systematic search through PubMed and EMBASE before 31 January 2025 was performed to identify eligible studies. Randomized controlled phase III trials comparing an anti-TROP-2 regimen to docetaxel in patients with pretreated advanced NSCLC were included. Overall survival (OS), progression-free survival (PFS), and grade \u2265 3 treatment-related adverse events (TRAEs) were extracted from the identified trials. A pooled analysis of reconstructed patient data and meta-analysis employing the random-effect model were used to summarize the efficacy and safety outcomes. Results: Across the two trials included, 1207 patients were enrolled, 598 in the TROP-2 ADC arm and 609 in the docetaxel arm. Anti-TROP-2 treatment did not produce significant improvements in OS (HR: 0.90; 95% CI, 0.78\u20131.03; P = 0.13) and PFS (HR: 0.84; 95% CI, 0.68\u20131.02; P = 0.08), compared to docetaxel, even in patients with a nonsquamous histology (OS HR: 0.86; 95% CI, 0.73\u20131.01; P = 0.06; PFS HR: 0.76; 95% CI, 0.52\u20131.12; P = 0.17). Across the subgroup analyses, a statistically significant improvement in OS was observed in patients with actionable genomic alterations (AGAs) (HR: 0.63; 95% CI, 0.41\u20130.95; P = 0.03). Compared to docetaxel, the anti-TROP-2 regimen demonstrated a lower risk of developing grade \u2265 3 TRAEs (RR: 0.76; 95% CI, 0.55\u20131.05; P = 0.09). Conclusions: The anti-TROP-2 regimen showed a better safety profile but failed to demonstrate a relevant clinical improvement over docetaxel. Anti-TROP-2 ADCs could find a role in the management of patients with AGAs.<\/jats:p>","DOI":"10.3390\/cancers17111750","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T06:35:09Z","timestamp":1747982109000},"page":"1750","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of TROP-2-Targeting Antibody\u2013Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7433-4347","authenticated-orcid":false,"given":"Sara","family":"Stumpo","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum\u2014University of Bologna, Via Zamboni 33, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4575-8300","authenticated-orcid":false,"given":"Andrea","family":"Carlini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum\u2014University of Bologna, Via Zamboni 33, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3111-5067","authenticated-orcid":false,"given":"Francesco","family":"Mantuano","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum\u2014University of Bologna, Via Zamboni 33, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-4315","authenticated-orcid":false,"given":"Alessandro","family":"Di Federico","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum\u2014University of Bologna, Via Zamboni 33, 40126 Bologna, Italy"},{"name":"Medical Oncology Unit, IRCCS Azienda Ospedaliero\u2014Universitaria di Bologna, Via P. Albertoni 15, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1041-391X","authenticated-orcid":false,"given":"Barbara","family":"Melotti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, IRCCS Azienda Ospedaliero\u2014Universitaria di Bologna, Via P. Albertoni 15, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1581-3456","authenticated-orcid":false,"given":"Francesca","family":"Sperandi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, IRCCS Azienda Ospedaliero\u2014Universitaria di Bologna, Via P. Albertoni 15, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5282-260X","authenticated-orcid":false,"given":"Valentina","family":"Favorito","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum\u2014University of Bologna, Via Zamboni 33, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0731-5721","authenticated-orcid":false,"given":"Andrea","family":"De Giglio","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum\u2014University of Bologna, Via Zamboni 33, 40126 Bologna, Italy"},{"name":"Medical Oncology Unit, IRCCS Azienda Ospedaliero\u2014Universitaria di Bologna, Via P. Albertoni 15, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1200\/EDBK_321483","article-title":"Immunotherapy for Advanced Non\u2013Small Cell Lung Cancer: A Decade of Progress","volume":"41","author":"Shields","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. B"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients with Advanced Non\u2013Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens","volume":"18","author":"Fossella","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus Nintedanib versus Docetaxel plus Placebo in Patients with Previously Treated Non-Small-Cell Lung Cancer (LUME-Lung 1): A Phase 3, Double-Blind, Randomised Controlled Trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S1326","DOI":"10.1016\/j.annonc.2021.08.2127","article-title":"LBA48 DUBLIN-3 (BPI-2358-103): A Global Phase (Ph) III Trial with the Plinabulin\/Docetaxel (Plin\/Doc) Combination vs. Doc in 2nd\/3rd Line NSCLC Patients (Pts) with EGFR-Wild Type (Wt) Progressing on a Prior Platinum-Based Regimen","volume":"32","author":"Han","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1556-0864(23)00260-5","article-title":"60 CONTACT-01: Efficacy and Safety from a Phase III Study of Atezolizumab (Atezo) + Cabozantinib (Cabo) Vs Docetaxel (Doc) Monotherapy in Patients (Pts) with Metastatic NSCLC (MNSCLC) Previously Treated with Checkpoint Inhibitors and Chemotherapy","volume":"18","author":"Neal","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"SAPPHIRE: Phase III Study of Sitravatinib plus Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"35","author":"Borghaei","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.21037\/atm-22-5976","article-title":"A Literature Review of the Promising Future of TROP2: A Potential Drug Therapy Target","volume":"10","author":"Wen","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and Its Overexpression in Cancers: Regulation and Clinical\/Therapeutic Implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1021\/jm800719t","article-title":"Antibody Conjugates of 7-Ethyl-10-Hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy","volume":"51","author":"Moon","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2\/SN-38 Antibody\u2013Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The Emergence of Trophoblast Cell-Surface Antigen 2 (TROP-2) as a Novel Cancer Target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective Extracellular Payload Release and Immunomodulatory Interactions Govern the Therapeutic Effect of Trastuzumab Deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase I\/II IMMU-132-01 Basket Trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yin, Y., Fan, Y., Ouyang, Q., Song, L., Wang, X., Li, W., Li, M., Yan, X., Wang, S., and Sun, T. (2025). Sacituzumab Tirumotecan in Previously Treated Metastatic Triple-Negative Breast Cancer: A Randomized Phase 3 Trial. Nat. Med.","DOI":"10.1038\/s41591-025-03630-w"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1200\/JCO.2025.43.5_suppl.796","article-title":"Efficacy and Safety of Sacituzumab Tirumotecan Monotherapy in Patients with Advanced Urothelial Carcinoma Who Progressed on or after Prior Anti-Cancer Therapies: Report from the Phase 1\/2 MK-2870-001 Study","volume":"43","author":"Ye","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study","volume":"42","author":"Mountzios","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non\u2013Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., and Brennan, S.E. (2021). The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. PLoS Med., 18.","DOI":"10.1371\/journal.pmed.1003583"},{"key":"ref_23","unstructured":"(2017). Common Terminology Criteria for Adverse Events (CTCAE) (v 5.0)."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: Reconstruct Individual Patient Data from Published Kaplan-Meier Survival Curves. BMC Med","volume":"21","author":"Liu","year":"2021","journal-title":"Res. Methodol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"28725","DOI":"10.18632\/oncotarget.15647","article-title":"Association of Tumor TROP2 Expression with Prognosis Varies among Lung Cancer Subtypes","volume":"8","author":"Inamura","year":"2017","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3892\/ol.2013.1368","article-title":"Expression and Clinical Significance of the Trop-2 Gene in Advanced Non-Small Cell Lung Carcinoma","volume":"6","author":"JIANG","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1200\/JCO.2023.41.16_suppl.3118","article-title":"The Genomic, Transcriptomic, and Immunological Landscape of TROP2 in Solid Tumors","volume":"41","author":"Trabolsi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","article-title":"TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer","volume":"30","author":"Bessede","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus Docetaxel for Patients with Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cllc.2018.05.011","article-title":"Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non\u2013Small-Cell Lung Cancer","volume":"19","author":"Bordoni","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.69854\/jcq.2024.0016","article-title":"Minimal Clinically Important Difference (MCID) of Effect Sizes Other than Mean Difference","volume":"1","author":"Horita","year":"2024","journal-title":"J. Clin. Quest."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic Non\u2013Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zhao, S., Cheng, Y., Wang, Q., Li, X., Liao, J., Rodon, J., Meng, X., Luo, Y., Chen, Z., and Wang, W. (2025). Sacituzumab Tirumotecan in Advanced Non-Small-Cell Lung Cancer with or without EGFR Mutations: Phase 1\/2 and Phase 2 Trials. Nat. Med.","DOI":"10.1038\/s41591-025-03638-2"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2022.05.011","article-title":"Treatment Strategies and Outcomes for Patients with EGFR-Mutant Non-Small Cell Lung Cancer Resistant to EGFR Tyrosine Kinase Inhibitors: Focus on Novel Therapies","volume":"170","author":"Johnson","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.19.03123","article-title":"Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review","volume":"38","author":"Sequist","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Itchins, M., and Pavlakis, N. (2022). The Quantum Leap in Therapeutics for Advanced ALK+ Non-Small Cell Lung Cancer and Pursuit to Cure with Precision Medicine. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.959637"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus Chemotherapy with and without Lazertinib in EGFR-Mutant Advanced NSCLC after Disease Progression on Osimertinib: Primary Results from the Phase III MARIPOSA-2 Study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor\u2013Mutated Non\u2013Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"104295","DOI":"10.1016\/j.critrevonc.2024.104295","article-title":"The Study of Primary and Acquired Resistance to First-Line Osimertinib to Improve the Outcome of EGFR-Mutated Advanced Non-Small Cell Lung Cancer Patients: The Challenge Is Open for New Therapeutic Strategies","volume":"196","author":"Ferro","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a Novel TROP2-Directed Antibody\u2013Drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.21037\/atm-21-1103","article-title":"Does Sacituzumab-Govitecan Act as a Conventional Antibody Drug Conjugate (ADC), a Prodrug of SN-38 or Both?","volume":"9","author":"Santi","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring Is Predictive of Clinical Outcomes in TROPION-Lung 01","volume":"19","author":"Garassino","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/JCO.2024.42.16_suppl.8501","article-title":"ICARUS-LUNG01: A Phase 2 Study of Datopotomab Deruxtecan (Dato-DXd) in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), with Sequential Tissue Biopsies and Biomarkers Analysis to Predict Treatment Outcome","volume":"42","author":"Planchard","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/11\/1750\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:38:58Z","timestamp":1760031538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/11\/1750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["cancers17111750"],"URL":"https:\/\/doi.org\/10.3390\/cancers17111750","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}